{
    "Clinical Trial ID": "NCT00971945",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment Arm",
        "  Paclitaxel 100 mg/m2 IV administered on Days 1, 8, 15, 22, 29, 36 and then suspended until Day 49 (1 course comprised of 49 days)."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants Experiencing Adverse Events",
        "  This outcome describes the number of participants experiencing any type, any grade, any cause adverse events (assessed both subjectively and objectively)",
        "  Time frame: From first dose to end of follow-up period (up to approximately 33 months)",
        "Results 1: ",
        "  Arm/Group Title: Treatment Arm",
        "  Arm/Group Description: Paclitaxel 100 mg/m2 IV administered on Days 1, 8, 15, 22, 29, 36 and then suspended until Day 49 (1 course comprised of 49 days).",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  6 100.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/6 (33.33%)",
        "  Nausea 1/6 (16.67%)",
        "  Vomiting 1/6 (16.67%)",
        "  Femur fracture 1/6 (16.67%)"
    ]
}